STOCK TITAN

Organogenesis (NASDAQ: ORGO) holder First Light reports 2.85% stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Organogenesis Holdings Inc. received an amended Schedule 13G from institutional investor First Light Asset Management, LLC and its control person, Mathew P. Arens, reporting their current ownership in the company’s common stock.

The filing shows First Light Asset Management may be deemed to beneficially own 3,611,616 shares, representing 2.85% of Organogenesis’ common stock. Mathew P. Arens may be deemed to beneficially own 3,888,816 shares, or 3.06% of the class, including 231,000 shares he holds directly and additional shares through joint and advised accounts.

The reporting persons certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Organogenesis. Because each now reports ownership below 5% of the outstanding shares, the filing confirms they are no longer large (5%+) shareholders.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



First Light Asset Management, LLC
Signature:/s/ Kurt T. Peterson
Name/Title:Kurt T. Peterson/Chief Compliance Officer
Date:02/17/2026
Mathew P. Arens
Signature:/s/ Mathew P. Arens
Name/Title:Mathew P. Arens/Chief Executive Officer
Date:02/17/2026
Exhibit Information

Exhibit A: Joint Filing Agreement

FAQ

What does the Schedule 13G/A filing report for Organogenesis (ORGO)?

The filing reports updated share ownership in Organogenesis common stock by First Light Asset Management and Mathew P. Arens. It shows both now hold under 5% of the outstanding shares, changing their status from large shareholders under U.S. securities rules.

How many Organogenesis (ORGO) shares does First Light Asset Management report owning?

First Light Asset Management may be deemed to beneficially own 3,611,616 Organogenesis common shares. This stake represents 2.85% of the company’s outstanding common stock, based on the figures provided in the filing’s ownership section under Item 4(a) and 4(b).

What is Mathew P. Arens’ reported ownership in Organogenesis (ORGO)?

Mathew P. Arens may be deemed to beneficially own 3,888,816 Organogenesis shares, or 3.06% of the class. This includes 231,000 shares he holds directly with sole control plus additional shares through joint accounts and entities he controls via First Light Asset Management.

Why did First Light and Mathew P. Arens file an amended Schedule 13G for ORGO?

They filed an amended Schedule 13G to update their beneficial ownership information under Rule 13d-1(b). The amendment reflects that each now holds less than 5% of Organogenesis’ common stock, requiring updated disclosure of their positions and voting and dispositive powers.

Do First Light and Mathew P. Arens seek to influence control of Organogenesis (ORGO)?

They certify the securities were acquired and are held in the ordinary course of business, not to change or influence control. The filing states the holdings are not in connection with, or as participants in, any transaction intended to affect control of Organogenesis Holdings Inc.

What voting and dispositive powers are reported over Organogenesis (ORGO) shares?

First Light reports shared voting and shared dispositive power over 3,611,616 shares, with no sole power. Mathew P. Arens reports sole voting and dispositive power over 231,000 shares and shared voting and dispositive power over 3,657,816 shares, reflecting his control of accounts advised by First Light.
Organogenesis Hldgs Inc

NASDAQ:ORGO

View ORGO Stock Overview

ORGO Rankings

ORGO Latest News

ORGO Latest SEC Filings

ORGO Stock Data

343.47M
67.38M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CANTON